Ipilimumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Melanoma, Hepatocellular Carcinoma, Colorectal Cancer, Renal Cell Carcinoma, Metastatic Colorectal Cancer, Esophageal Squamous Cell Carcinoma, Cutaneous Melanoma, Advanced Metastatic Colorectal Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Urothelial Carcinoma · Phase 3

Also approved (4)
US
  • Malignant Pleural Mesothelioma YERVOY, in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.
Product first approved 2011Outside this platform's coverageFDA label
JP
  • Unresectable melanoma
Product first approved 2015ono-pharma.com
CA
  • PrYERVOY® (ipilimumab for injection) is indicated for: Unresectable or Metastatic Melanoma: • Yervoy as a single agent is indicated for the treatment of unresectable or metastatic melanoma. • Yervoy in combination with nivolumab is indicated for the treatment of adult patients with unresectable or metastatic melanoma who have not received prior systemic therapy for unresectable or metastatic melanoma. o When using Yervoy in combination with nivolumab, consult Product Monograph for nivolumab for further information on this drug. Metastatic Renal Cell Carcinoma (RCC): • Yervoy, in...
Product first approved 2012Health Canada
EU
  • Advanced melanoma (first EU indication; EPAR now lists further cancers)
Product first approved 2011EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (57)
Advanced Metastatic Colorectal Cancer
Cutaneous Melanoma
NCT02224781 · National Cancer Institute (NCI)
2015-09-08 – 2026-12-19 · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
What this study did
Hepatocellular Carcinoma
Melanoma
NCT06794775 · Hildur Helgadottir
2025-07-10 – 2032-04-15 · Malignant Melanoma Stage III
What this study did
NCT04949113 · The Netherlands Cancer Institute
2021-07-08 – 2028-12-19 · Malignant Melanoma Stage III
What this study did
NCT03445533 · Idera Pharmaceuticals, Inc.
2018-05-30 – 2021-06-01 · Metastatic Melanoma
What this study did
NCT02599402 · Bristol-Myers Squibb
2015-12-20 – 2020-02-10 · Melanoma
What this study did
NCT02460068 · Italian Network for Tumor Biotherapy Foundation
2012-12 – 2020-01 · Brain Metastases
What this study did
NCT02905266 · Bristol-Myers Squibb
2016-10-27 – 2019-10-25 · Melanoma
What this study did
NCT02545075 · Bristol-Myers Squibb
2015-10-31 – 2019-04-19 · Melanoma
What this study did
NCT00636168 · Bristol-Myers Squibb
2008-06-30 – 2018-11-26 · High Risk Stage III Melanoma
What this study did
NCT01515189 · Bristol-Myers Squibb
2012-02-17 – 2017-08-17 · Melanoma
What this study did
NCT00324155 · Bristol-Myers Squibb
2006-08 – 2013-10 · Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT03391869 · M.D. Anderson Cancer Center
2017-12-29 – 2027-03-31 · Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT03469960 · Intergroupe Francophone de Cancerologie Thoracique
2018-05-02 – 2025-10-15 · Non-Small Cell Lung Cancer Metastatic
What this study did
NCT03520686 · ImmunityBio, Inc.
2018-05-18 – 2025-10-13 · Non Small Cell Lung Cancer
What this study did
NCT02998528 · Bristol-Myers Squibb
2017-03-04 – 2024-12-06 · Non Small Cell Lung Cancer
What this study did
NCT04026412 · Bristol-Myers Squibb
2019-10-08 – 2024-11-26 · Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT03302234 · Merck Sharp & Dohme LLC
2017-12-14 – 2022-09-07 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT03351361 · Rennes University Hospital
2018-02-19 – 2022-07-31 · Advanced Non Small Cell Lung Cancer
What this study did
NCT03048136 · Bristol-Myers Squibb
2018-03-09 – 2019-09-29 · Non-Small Cell Lung Cancer
What this study did
Renal Cell Carcinoma
NCT03793166 · National Cancer Institute (NCI)
2019-06-07 – 2028-03-01 · Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
What this study did
NCT03873402 · Bristol-Myers Squibb
2019-06-21 – 2027-03-11 · Renal Cell Carcinoma
What this study did
NCT03141177 · Bristol-Myers Squibb
2017-07-23 – 2026-04-01 · Renal Cell Carcinoma
What this study did
Urothelial Carcinoma
Other / comorbidity
NCT06364631 · Gustave Roussy, Cancer Campus, Grand Paris
2024-04-12 – 2032-05-05 · Metastatic Kidney Cancer, Metastatic Kidney Carcinoma
What this study did
NCT06490536 · IFOM ETS - The AIRC Institute of Molecular Oncology
2024-10-22 – 2028-09-01 · Colon Cancer Stage II, Colon Cancer Stage III
What this study did
NCT02785952 · SWOG Cancer Research Network
2015-12-29 – 2027-04-01 · Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
What this study did
NCT04741438 · Centre Leon Berard
2021-03-30 – 2025-08 · Sarcoma
What this study did
NCT02017717 · Bristol-Myers Squibb
2014-02-07 – 2024-06-21 · Recurrent Glioblastoma
What this study did
NCT02872116 · Bristol-Myers Squibb
2016-10-12 – 2024-06-06 · Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
What this study did
NCT03700905 · Universitätsklinikum Hamburg-Eppendorf
2018-08-21 – 2024-05 · Head and Neck Cancer
What this study did
Phase 2/3 (12)
Advanced Metastatic Colorectal Cancer
NCT05141721 · Seattle Project Corporation
2022-02-12 – 2027-03 · Colorectal Neoplasms
What this study did
Cutaneous Melanoma
NCT02339571 · National Cancer Institute (NCI)
2015-11-23 – 2033-06-30 · Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
What this study did
Hepatocellular Carcinoma
NCT05665348 · Federation Francophone de Cancerologie Digestive
2023-03-09 – 2025-05-12 · HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor
What this study did
Melanoma
Non-Small Cell Lung Cancer
NCT04929041 · National Cancer Institute (NCI)
2022-10-07 – 2030-12-12 · Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
Other / comorbidity
NCT07879586 · Yao Hongwei
2026-10-01 – 2032-10-01 · Locally Advanced Rectal Cancer (LARC)
What this study did
NCT07643623 · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
2026-07-31 – 2031-12-31 · Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03604991 · National Cancer Institute (NCI)
2019-05-03 – 2027-03-31 · Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT04396860 · National Cancer Institute (NCI)
2020-09-01 – 2025-12-23 · Gliosarcoma, MGMT-Unmethylated Glioblastoma
What this study did
NCT04887870 · Mirati Therapeutics Inc.
2021-06-29 – 2025-09-25 · Advanced or Metastatic Solid Malignancies
What this study did
NCT03879122 · Spanish Oncology Genito-Urinary Group
2019-02-11 – 2024-12-31 · Metastatic Hormone-sensitive Prostate Cancer
What this study did
Phase 2 (361)
Advanced Metastatic Colorectal Cancer
NCT07506109 · Tianjin Medical University Cancer Institute and Hospital
2026-03-01 – 2028-06 · BRAF V600E, Colorectal Cancer, Sintilimab, MSS (Microsatellite Stable), Cetuximab, Dabrafenib, Ipilimumab N01
What this study did
NCT05310643 · GERCOR - Multidisciplinary Oncology Cooperative Group
2022-05-05 – 2027-09 · Metastatic Colorectal Cancer
What this study did
NCT03350126 · GERCOR - Multidisciplinary Oncology Cooperative Group
2017-12-04 – 2025-12 · Metastatic Cancer Colorectal
What this study did
NCT03832621 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
2019-03-25 – 2021-09-30 · Metastatic Colorectal Cancer
What this study did
NCT04430985 · Dorte Nielsen
2020-09-30 – 2021-09-06 · Metastatic Colorectal Cancer
What this study did
Colorectal Cancer
NCT07403877 · Fudan University
2026-02-01 – 2034-12-31 · Colorectal Cancer (MSI-H)
What this study did
NCT04730544 · GERCOR - Multidisciplinary Oncology Cooperative Group
2021-05-21 – 2028-04 · Colorectal Cancer Metastatic, MSI-H Colorectal Cancer
What this study did
NCT03104439 · Massachusetts General Hospital
2017-05-10 – 2027-04 · Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, MSI High Colorectal Cancer
What this study did
NCT06410534 · National Cancer Institute (NCI)
2025-09-09 – 2025-09-09 · Colorectal Cancer, Gastroesophageal Cancer
What this study did
NCT02060188 · Bristol-Myers Squibb
2014-03-12 – 2024-10-22 · Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
What this study did
NCT04575922 · Massachusetts General Hospital
2020-10-05 – 2024-06 · Metastatic Microsatellite Stable Colorectal Cancer
What this study did
NCT05456165 · Gritstone bio, Inc.
2022-05-19 – 2022-09-01 · Colonic Neoplasms, Colorectal Neoplasms
What this study did
Cutaneous Melanoma
NCT06999980 · Melanoma Institute Australia
2026-02-09 – 2038-01 · Cutaneous Melanoma, Mucosal Melanoma
What this study did
NCT07230613 · UNICANCER
2026-01-12 – 2033-12 · Cutaneous Melanoma, Stage III, Mucosal Melanoma
What this study did
NCT04462406 · ECOG-ACRIN Cancer Research Group
2021-02-09 – 2030-09-30 · Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
What this study did
NCT07155317 · Emory University
2025-10-29 – 2027-12-31 · Advanced Acral Melanoma, Advanced Cutaneous Melanoma, Advanced Mucosal Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Acral Melanoma, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Mucosal Melanoma
What this study did
NCT04511013 · SWOG Cancer Research Network
2021-01-06 – 2027-06-30 · Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
What this study did
NCT01708941 · National Cancer Institute (NCI)
2013-03-25 – 2026-05-26 · Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
What this study did
NCT03873818 · M.D. Anderson Cancer Center
2019-02-21 – 2025-08-21 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
What this study did
NCT03719131 · Emory University
2019-06-05 – 2025-04-09 · Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Stage III Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma, Unresectable Melanoma
What this study did
NCT05200143 · Providence Health & Services
2022-06-08 – 2024-07-23 · Refractory Cutaneous Melanoma
What this study did
NCT02027935 · M.D. Anderson Cancer Center
2015-01-22 – 2024-04-12 · Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
What this study did
NCT02519322 · M.D. Anderson Cancer Center
2016-02-02 – 2023-01-26 · Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage III Acral Lentiginous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Acral Lentiginous Melanoma AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
What this study did
NCT03396952 · University of California, San Francisco
2018-04-19 – 2022-06-30 · Stage III Cutaneous Melanoma, Stage IIIA Cutaneous Melanoma, Stage IIIB Cutaneous Melanoma, Stage IIIC Cutaneous Melanoma, Stage IV Cutaneous Melanoma
What this study did
NCT02158520 · Academic and Community Cancer Research United
2013-10-18 – 2019-10-30 · Metastatic Melanoma, Mucosal Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7, Unresectable Melanoma
What this study did
Esophageal Squamous Cell Carcinoma
NCT07751055 · Sun Yat-sen University
2026-08-01 – 2030-12-31 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
Hepatocellular Carcinoma
NCT06492408 · Second Affiliated Hospital of Guangzhou Medical University
2024-07-01 – 2033-12-30 · Hepatic Cancer, Surgery
What this study did
NCT07689175 · University of Texas Southwestern Medical Center
2026-08-21 – 2032-10-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07919717 · Shanghai Zhongshan Hospital
2026-11-01 – 2029-04-12 · Hepatocellular Carcinoma (HCC), Recurrent Hepatocellular Cancer
What this study did
NCT07422753 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-03-25 – 2029-03 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07560488 · Tianjin Medical University Cancer Institute and Hospital
2026-03-30 – 2028-04 · HCC - Hepatocellular Carcinoma, Conversion Therapy
What this study did
NCT07487662 · Sun Yat-sen University
2026-03-20 – 2028-03-19 · Hepato Cellular Carcinoma (HCC)
What this study did
NCT04472767 · University of California, Irvine
2020-08-07 – 2027-09-01 · Hepatocellular Carcinoma, HCC
What this study did
NCT05199285 · Academic and Community Cancer Research United
2023-01-19 – 2026-02-01 · BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
What this study did
NCT03510871 · National Health Research Institutes, Taiwan
2019-02-12 – 2024-05-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05302921 · Children's National Research Institute
2022-02-18 – 2024-03-12 · Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Melanoma, Hepatoblastoma, Hepatocellular Carcinoma, Neuroblastoma, Wilms Tumor
What this study did
NCT03222076 · M.D. Anderson Cancer Center
2017-09-28 – 2022-09-14 · Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
What this study did
Melanoma
NCT07504796 · NYU Langone Health
2026-04-13 – 2031-05 · Metastatic Melanoma, Advanced Melanoma
What this study did
NCT07930182 · H. Lee Moffitt Cancer Center and Research Institute
2026-10-21 – 2030-10-21 · Melanoma
What this study did
NCT07511036 · M.D. Anderson Cancer Center
2026-09-01 – 2030-05-24 · Melanoma
What this study did
NCT06712927 · Stanford University
2025-08-06 – 2030-02 · Melanoma, Brain Metastases
What this study did
NCT04562129 · H. Lee Moffitt Cancer Center and Research Institute
2020-09-24 – 2029-11 · Melanoma Stage III, Melanoma Stage IV, Inoperable Disease
What this study did
NCT03340129 · Melanoma Institute Australia
2019-08-14 – 2029-08 · Melanoma Stage Iv
What this study did
NCT07740941 · UNC Lineberger Comprehensive Cancer Center
2026-08-06 – 2029-03 · Melanoma (Skin Cancer), Melanoma Stage Stage IIIB, Melanoma Stage M1, Melanoma Stage IV
What this study did
NCT06250335 · M.D. Anderson Cancer Center
2024-03-01 – 2029-01-23 · ICB-refractory Melanoma
What this study did
NCT02374242 · Melanoma Institute Australia
2014-11-04 – 2028-12 · Melanoma, Brain Metastases
What this study did
NCT06295159 · H. Lee Moffitt Cancer Center and Research Institute
2024-05-17 – 2028-11 · Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
What this study did
NCT03563729 · Inge Marie Svane
2018-06-06 – 2028-06-06 · Malignant Melanoma
What this study did
Phase 1/2 (126)
Colorectal Cancer
NCT05187338 · Second Affiliated Hospital of Guangzhou Medical University
2021-11-01 – 2035-10-30 · Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer, Ovary Cancer, Head and Neck Cancer, Breast Cancer, Gastric Cancer, Cervical Cancer, Esophageal Cancer, Sarcoma
What this study did
NCT03377361 · Bristol-Myers Squibb
2018-01-31 – 2024-11-04 · Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
What this study did
Cutaneous Melanoma
NCT05896839 · National Cancer Institute (NCI)
2024-07-24 – 2027-08-02 · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Basal Cell Carcinoma, Metastatic Carcinoma in the Skin, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Unresectable Basal Cell Carcinoma, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma
What this study did
NCT02304458 · National Cancer Institute (NCI)
2015-03-30 – 2023-03-31 · Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdomyosarcoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
What this study did
NCT03326258 · National Cancer Institute (NCI)
2018-04-20 – 2018-04-20 · Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative, GPNMB Positive, HER2/Neu Negative, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Progesterone Receptor Negative, Stage III Breast Cancer AJCC v7, Stage III Cutaneous Melanoma AJCC v7, Stage III Uveal Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7, Triple-Negative Breast Carcinoma, Unresectable Solid Neoplasm
What this study did
Esophageal Squamous Cell Carcinoma
NCT06047379 · Neonc Technologies, Inc.
2023-11-01 – 2027-08-31 · Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
What this study did
Hepatocellular Carcinoma
NCT07227012 · Pfizer
2025-12-01 – 2028-10-17 · Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Liver Neoplasms, Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
What this study did
NCT07482059 · West China Hospital
2026-02 – 2028-06-30 · Unresectable Hepatocellular Carcinoma
What this study did
NCT03682276 · Imperial College London
2019-03-01 – 2026-03-12 · Hepatocellular Carcinoma
What this study did
NCT05220722 · TriSalus Life Sciences, Inc.
2022-03-02 – 2024-07-31 · Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
What this study did
Melanoma
NCT06240143 · The Netherlands Cancer Institute
2024-03-08 – 2034-03 · Melanoma
What this study did
NCT06683755 · M.D. Anderson Cancer Center
2024-12-31 – 2032-08-16 · Melanoma
What this study did
NCT06163820 · Melanoma and Skin Cancer Trials Limited
2026-08-31 – 2030-01-30 · Melanoma Brain Metastases
What this study did
NCT04283890 · Leiden University Medical Center
2019-12-04 – 2029-12 · Uveal Melanoma, Metastatic
What this study did
NCT07615881 · Amsterdam UMC, location VUmc
2026-07 – 2029-07 · Melanoma (Skin Cancer)
What this study did
NCT06784648 · BioInvent International AB
2024-12-11 – 2027-07-30 · Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent, Melanoma Stage III or IV, Melanoma, Melanoma Negative for bRAF, Melanoma Negative for nRAS, Melanomas, Uveal Melanoma, Metastatic
What this study did
NCT04464759 · Ravi Amaravadi, MD
2020-10-21 – 2027-05-12 · Melanoma
What this study did
NCT03958383 · University of Wisconsin, Madison
2020-01-30 – 2025-12-09 · Melanoma
What this study did
NCT03400332 · Bristol-Myers Squibb
2018-02-12 – 2025-12-04 · Cancer, Melanoma
What this study did
NCT04060407 · Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2021-06-15 – 2023-12-30 · Metastatic Melanoma
What this study did
NCT03161756 · Melanoma and Skin Cancer Trials Limited
2017-12-07 – 2023-12 · Melanoma Stage Iv, Melanoma Stage Iii, Melanoma
What this study did
NCT02913417 · David Minor, MD
2016-10-10 – 2023-06 · Uveal Melanoma, Hepatic Metastases
What this study did
NCT02857569 · Gustave Roussy, Cancer Campus, Grand Paris
2016-12-05 – 2022-05-20 · Stage III/IV Melanoma
What this study did
NCT03949153 · University Hospital, Strasbourg, France
2019-08-16 – 2022-03-18 · Melanoma (Skin)
What this study did
NCT02275416 · Ultimovacs ASA
2015-02-02 – 2020-11-03 · Malignant Melanoma
What this study did
NCT03297463 · Masonic Cancer Center, University of Minnesota
2018-01-31 – 2020-02-01 · Metastatic Melanoma, Pulmonary Metastases, Hepatic Metastases, Brain Metastases
What this study did
NCT02385669 · Craig L Slingluff, Jr
2015-04 – 2019-09-18 · Melanoma
What this study did
NCT02073123 · NewLink Genetics Corporation
2014-07 – 2019-07-03 · Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
What this study did
NCT02941744 · Universitair Ziekenhuis Brussel
2016-03 – 2019-01 · Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
What this study did
NCT02452281 · Rabih Said
2015-12 – 2018-12 · Melanoma
What this study did
NCT02259231 · Biogen
2014-10-31 – 2018-07-23 · Melanoma, Unresectable (Stage III) Melanoma, Metastatic (Stage IV) Melanoma
What this study did
NCT02736123 · University of Pittsburgh
2016-10 – 2017-02-09 · Melanoma
What this study did
NCT02413827 · Celldex Therapeutics
2015-04 – 2016-11-09 · Unresectable Stage III or Stage IV Melanoma
What this study did
NCT02009397 · University of Louisville
2012-02 – 2016-11 · Metastatic Melanoma
What this study did
NCT01409187 · M.D. Anderson Cancer Center
2011-10 – 2016-10 · Melanoma
What this study did
NCT01497808 · Abramson Cancer Center at Penn Medicine
2011-11-29 – 2015-10-12 · Metastatic Melanoma
What this study did
NCT01590082 · M.D. Anderson Cancer Center
2012-11 – 2015-07 · Melanoma
What this study did
NCT01689870 · Ludwig Institute for Cancer Research
2014-03 – 2014-08 · Metastatic Melanoma
What this study did
NCT00871481 · Fred Hutchinson Cancer Center
2009-02 – 2013-10 · Recurrent Melanoma, Stage IV Melanoma
What this study did
NCT01743157 · California Pacific Medical Center Research Institute
2010-12 – 2013-05 · Metastatic Melanoma
What this study did
NCT00261365 · Bristol-Myers Squibb
2005-11 – 2007-10 · Unresectable Stage III or IV Malignant Melanoma
What this study did
NCT00058279 · National Cancer Institute (NCI)
2003-02 – 2006-08 · Intraocular Melanoma, Melanoma (Skin)
What this study did
Non-Small Cell Lung Cancer
NCT07355205 · Washington University School of Medicine
2026-07-07 – 2032-07-31 · Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
What this study did
NCT04665206 · Vivace Therapeutics, Inc
2021-03-24 – 2030-03-02 · Solid Tumor, Adult, Mesothelioma, NSCLC, Pleural Mesothelioma, Non-Pleural Mesothelioma, Non Small Cell Lung Cancer, Epithelioid Hemangioendothelioma (EHE), Adenoma, Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neoplasms, Mesothelial
What this study did
NCT07563738 · Orion Corporation, Orion Pharma
2026-03-27 – 2029-09 · Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
Phase 1 (215)
Advanced Metastatic Colorectal Cancer
NCT07587827 · Centre Georges Francois Leclerc
2026-11-01 – 2031-05-01 · Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Cancer
What this study did
NCT04362839 · City of Hope Medical Center
2020-05-27 – 2025-12-11 · Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8
What this study did
NCT03507699 · Sheba Medical Center
2018-12-15 – 2022-05-25 · Colorectal Neoplasms Malignant, Liver Metastases
What this study did
Colorectal Cancer
NCT04117087 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2020-05-28 – 2027-06-01 · Colorectal Cancer, Pancreatic Cancer
What this study did
NCT04721301 · University Hospital Heidelberg
2017-01-15 – 2023-03-15 · Colorectal Cancer Metastatic, Pancreatic Cancer Metastatic
What this study did
NCT03373188 · Emory University
2017-12-15 – 2021-10-28 · Colon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
What this study did
NCT03982121 · Gustave Roussy, Cancer Campus, Grand Paris
2019-06-04 – 2020-02-12 · Colorectal Cancer Metastatic
What this study did
Cutaneous Melanoma
NCT03769155 · Emory University
2018-12-13 – 2032-12-15 · Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
What this study did
NCT03929029 · Dana-Farber Cancer Institute
2020-11-11 – 2028-09-30 · Cutaneous Melanoma
What this study did
NCT04697576 · Carlo Contreras
2021-10-20 – 2027-12-31 · Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
What this study did
NCT03816332 · National Cancer Institute (NCI)
2019-11-08 – 2027-09-17 · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Basal Cell Carcinoma, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Unresectable Basal Cell Carcinoma, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma
What this study did
NCT05341349 · Emory University
2022-10-13 – 2024-05-31 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Ocular Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
What this study did
NCT04967196 · Mayo Clinic
2021-09-16 – 2024-04-17 · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Unresectable Melanoma
What this study did
NCT01738139 · M.D. Anderson Cancer Center
2013-02-19 – 2023-12-13 · Advanced Malignant Solid Neoplasm, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Gastrointestinal Stromal Tumor, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma, Unresectable Solid Neoplasm
What this study did
NCT01940809 · National Cancer Institute (NCI)
2013-08-28 – 2022-03-04 · BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
What this study did
NCT03425461 · Jonsson Comprehensive Cancer Center
2018-06-14 – 2021-03-04 · Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
What this study did
Hepatocellular Carcinoma
NCT04248569 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2020-04-20 – 2034-03-01 · Fibrolamellar Hepatocellular Carcinoma (FLC)
What this study did
NCT07430202 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2026-10-28 – 2030-10 · Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
What this study did
NCT07075120 · University of Hawaii
2026-04-01 – 2027-12-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05909995 · Incyte Corporation
2023-08-29 – 2024-11-11 · Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Microsatellite Instability - High (MSI-H), Mismatch Repair Deficient (dMMR), Colorectal Carcinoma (CRC)
What this study did
NCT04823403 · Gustave Roussy, Cancer Campus, Grand Paris
2020-11-13 – 2024-11 · Hepatocellular Carcinoma
What this study did
NCT03203304 · University of Chicago
2017-08-25 – 2019-03-13 · Hepatocellular Carcinoma
What this study did
Melanoma
NCT07838974 · University of Southern California
2026-11-01 – 2030-11-01 · Melanoma
What this study did
NCT07501117 · Inge Marie Svane
2026-06-29 – 2029-06-01 · Uveal Melanoma
What this study did
NCT05498792 · Fox Chase Cancer Center
2022-11-30 – 2027-09-02 · Locally Advanced or Metastatic Melanoma
What this study did
NCT06377111 · University Health Network, Toronto
2024-06-24 – 2027-08 · Melanoma (Skin)
What this study did
NCT02668770 · M.D. Anderson Cancer Center
2016-05-11 – 2025-11-05 · Advanced Cancers, Melanoma
What this study did
NCT03068624 · M.D. Anderson Cancer Center
2017-09-08 – 2025-07-31 · Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
What this study did
NCT05004025 · HonorHealth Research Institute
2022-02-28 – 2025-07-23 · Uveal Melanoma
What this study did
NCT02437279 · The Netherlands Cancer Institute
2016-11-24 – 2025-06 · Stage III Skin Melanoma
What this study did
NCT04223648 · Yale University
2020-08-15 – 2025-02 · Malignant Melanoma
What this study did
NCT05704933 · H. Lee Moffitt Cancer Center and Research Institute
2023-06-06 – 2024-08-20 · Metastatic Melanoma, Metastasis to Brain
What this study did
NCT04463368 · Vastra Gotaland Region
2021-03-08 – 2024-07-26 · Uveal Melanoma, Liver Metastases
What this study did
NCT05169957 · University of Michigan Rogel Cancer Center
2022-08-09 – 2024-07-17 · Melanoma, Ocular, Melanoma, Cutaneous, Metastatic Melanoma, Melanoma, Mucosal, Liver Metastases
What this study did
NCT04935229 · TriSalus Life Sciences, Inc.
2021-08-02 – 2024-07-17 · Metastatic Uveal Melanoma in the Liver
What this study did
NCT03922880 · Memorial Sloan Kettering Cancer Center
2019-04-16 – 2023-01-20 · Uveal Melanoma
What this study did
NCT01176474 · H. Lee Moffitt Cancer Center and Research Institute
2010-08-13 – 2023-01-06 · Melanoma (Skin)
What this study did
NCT03526185 · Yale University
2018-02-06 – 2020-12-01 · Metastatic Melanoma
What this study did
NCT03597282 · BioNTech US Inc.
2018-10-08 – 2020-08-11 · Metastatic Melanoma
What this study did
NCT02659540 · Ludwig Institute for Cancer Research
2016-10-13 – 2020-07-27 · Melanoma
What this study did
NCT02210104 · M.D. Anderson Cancer Center
2016-12 – 2019-12 · Melanoma, Sarcoma
What this study did
NCT02307149 · Viralytics
2015-05-05 – 2019-11-05 · Melanoma
What this study did
NCT02032810 · H. Lee Moffitt Cancer Center and Research Institute
2014-01-07 – 2019-09-25 · Melanoma, Skin Cancer
What this study did
NCT03408587 · Viralytics
2018-01-29 – 2019-05-22 · Uveal Melanoma, Liver Metastases
What this study did
NCT01024231 · Bristol-Myers Squibb
2009-12-14 – 2019-04-01 · Malignant Melanoma
What this study did
NCT03098160 · Threshold Pharmaceuticals
2017-05-10 – 2019-04 · Pancreatic Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Prostate Cancer
What this study did
NCT02117362 · Providence Health & Services
2014-05-08 – 2018-11-28 · Metastatic Melanoma
What this study did
NCT01621490 · Bristol-Myers Squibb
2012-09-27 – 2018-10-25 · Advanced Melanoma, Metastatic Melanoma
What this study did
Phase 4 (6)
Melanoma
NCT02068196 · Oslo University Hospital
2014-01 – 2026-12 · Malignant Melanoma
What this study did
NCT01856023 · Clinigen, Inc.
2013-05 – 2015-07 · Metastatic Melanoma
What this study did
Renal Cell Carcinoma
NCT02982954 · Bristol-Myers Squibb
2017-01-16 – 2021-10-06 · Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT06031233 · Isala
2023-09-01 – 2028-12 · Oncology, Infusion Reaction
What this study did
NCT04513522 · Bristol-Myers Squibb
2020-12-17 – 2024-01-04 · Kidney Neoplasms
What this study did
NCT02869789 · Bristol-Myers Squibb
2016-10-05 – 2022-05-13 · Lung Cancer
What this study did
Early phase / not applicable (14)
Melanoma
NCT07564570 · Universitätsklinikum Hamburg-Eppendorf
2025-11-14 – 2028-12-31 · Metastatic Melanoma
What this study did
NCT07364474 · Massachusetts General Hospital
2026-01-27 – 2028-09 · Uveal Melanoma
What this study did
NCT07422779 · Institute of Oncology Ljubljana
2022-03-01 – 2028-03-31 · Metastatic Melanoma, Skin Cancer
What this study did
NCT01701674 · H. Lee Moffitt Cancer Center and Research Institute
2012-10-09 – 2025-08-21 · Metastatic Melanoma
What this study did
NCT07436390 · Institute of Oncology Ljubljana
2024-03-31 – 2024-03-31 · Metastatic Melanoma, Malignant Melanoma, Skin Cancer
What this study did
NCT03225365 · Hospices Civils de Lyon
2019-10-10 – 2021-06-15 · Metastatic Melanoma
What this study did
NCT01715077 · University Health Network, Toronto
2012-10 – 2017-10 · Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma
What this study did
Renal Cell Carcinoma
NCT07233668 · Seoul National University Hospital
2025-12-01 – 2029-02-01 · Metastatic Renal Cell Carcinoma ( mRCC)
What this study did
NCT05119010 · Gustave Roussy, Cancer Campus, Grand Paris
2023-03-24 – 2024-05-22 · Metastatic Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT06353646 · Wu Wenming
2024-03-12 – 2026-12 · Pancreatic Cancer
What this study did
NCT04256213 · ARCAGY/ GINECO GROUP
2020-07-02 – 2024-08-04 · Cervix Cancer
What this study did
NCT02833233 · Memorial Sloan Kettering Cancer Center
2016-06 – 2024-06-07 · Breast Cancer
What this study did
Used as active comparator (20)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (6)
Cutaneous Melanoma
NCT06743126 · Immatics US, Inc.
2025-01-14 – 2032-08-12 · Melanoma, Cutaneous Malignant, Mucosal Melanoma
What this study did
NCT02506153 · National Cancer Institute (NCI)
2015-11-10 – 2027-01-23 · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Metastatic Non-Cutaneous Melanoma, Non-Cutaneous Melanoma, Recurrent Cutaneous Melanoma, Recurrent Mucosal Melanoma, Recurrent Non-Cutaneous Melanoma
What this study did
Hepatocellular Carcinoma
NCT06841185 · Shanghai Henlius Biotech
2025-04-30 – 2028-05-05 · Hepatocellular Carcinoma (HCC)
What this study did
Melanoma
NCT02278887 · The Netherlands Cancer Institute
2014-09-23 – 2023-12-31 · Metastatic Melanoma
What this study did
Other / comorbidity
NCT06097728 · AstraZeneca
2023-11-09 – 2028-11-16 · Unresectable Pleural Mesothelioma
What this study did
NCT04334759 · PrECOG, LLC.
2021-02-18 – 2025-06-30 · Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
What this study did
Phase 2/3 (2)
Cutaneous Melanoma
NCT06624644 · Linnaeus Therapeutics, Inc.
2025-08-06 – 2031-02 · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma
What this study did
Melanoma
NCT05987332 · IDEAYA Biosciences
2023-10-31 – 2028-01-15 · Metastatic Uveal Melanoma
What this study did
Phase 2 (5)
Melanoma
NCT03070392 · Immunocore Ltd
2017-10-16 – 2025-09-17 · Uveal Melanoma
What this study did
NCT02054520 · NewLink Genetics Corporation
2014-06 – 2021-01-05 · Stage IV Melanoma, Metastatic Melanoma
What this study did
Renal Cell Carcinoma
NCT05928806 · Michael B. Atkins, MD
2023-09-25 – 2027-11-10 · Advanced Renal Cell Carcinoma
What this study did
NCT02996110 · Bristol-Myers Squibb
2017-02-02 – 2021-11-23 · Advanced Cancer
What this study did
Phase 1/2 (2)
Melanoma
NCT05116202 · Hoffmann-La Roche
2022-02-02 – 2024-05-28 · Melanoma
What this study did
Phase 1 (5)
Hepatocellular Carcinoma
Other / comorbidity
NCT07852325 · The Affiliated Hospital of Qingdao University
2024-01-07 – 2024-12-19 · Healthy Participants
What this study did
NCT06159101 · Shanghai Henlius Biotech
2023-11-28 – 2024-05-28 · Healthy Male Volunteers
What this study did
NCT03798639 · Claire Verschraegen
2019-01-07 – 2022-12-02 · Merkel Cell Carcinoma, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
What this study did
NCT04868760 · Innovent Biologics (Suzhou) Co. Ltd.
2021-05-31 – 2022-05-02 · Healthy Subjects
What this study did
Appears in other studies (17)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (4)
Hepatocellular Carcinoma
NCT07166406 · NRG Oncology
2026-02-26 – 2034-03-10 · Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
What this study did
Melanoma
NCT07815574 · Scancell Ltd
2026-12-01 – 2032-12-01 · Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
What this study did
Renal Cell Carcinoma
NCT07383441 · SWOG Cancer Research Network
2026-06-05 – 2034-01-31 · Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
What this study did
NCT03937219 · Exelixis
2019-06-25 – 2027-01-31 · Renal Cell Carcinoma
What this study did
Phase 2 (10)
Cutaneous Melanoma
NCT01134614 · National Cancer Institute (NCI)
2010-12-28 – 2027-03-19 · Advanced Melanoma, Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
What this study did
NCT01950390 · National Cancer Institute (NCI)
2014-01-24 – 2025-01-31 · Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
What this study did
NCT03033576 · National Cancer Institute (NCI)
2017-10-23 – 2024-03-20 · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Mucosal Melanoma, Unresectable Cutaneous Melanoma, Unresectable Melanoma
What this study did
Melanoma
NCT02498756 · The First People's Hospital of Changzhou
2015-08 – 2040-08 · Melanoma
What this study did
NCT03646617 · Abramson Cancer Center at Penn Medicine
2018-11-27 – 2027-12-31 · Metastatic Melanoma
What this study did
NCT03693014 · Memorial Sloan Kettering Cancer Center
2018-10-01 – 2027-10 · Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer, Renal Cancer, Head/Neck Cancers
What this study did
Non-Small Cell Lung Cancer
NCT07603856 · University of Chicago
2026-12-12 – 2030-06-25 · Non-Small Cell Lung Cancer, Metastatic Lung Cancer
What this study did
Renal Cell Carcinoma
NCT05327686 · NRG Oncology
2023-02-01 – 2033-06-15 · Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT06482801 · Second Affiliated Hospital of Guangzhou Medical University
2024-06-10 – 2035-12-30 · Liver Cancer, Antibody
What this study did
NCT06483347 · Second Affiliated Hospital of Guangzhou Medical University
2024-04-04 – 2033-12-30 · Lung Cancer, Inoperable Disease
What this study did
Phase 1/2 (1)
Melanoma
NCT01740297 · Amgen
2013-02-07 – 2021-03-09 · Melanoma
What this study did
Phase 1 (2)
Melanoma
NCT03293784 · Institut Claudius Regaud
2017-10-16 – 2023-08-10 · Melanoma
What this study did
Other / comorbidity
NCT03728179 · Centre Hospitalier Universitaire Vaudois
2019-01-16 – 2023-10-27 · Solid Tumor, Adult
What this study did

Competitive landscape

This drug's own stage for Advanced Metastatic Colorectal Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ipilimumab: this drugApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
BafisontamabPhase 2Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
PelareorepPhase 2Oncolytic virusTumor cells (oncolytic replication)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(167 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ipilimumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (16)
November 2026 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2026-11 · NCT06712927 · CT.gov ↗
What to watch
December 2026 (15)
Phase 1Stage IV Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03223155 · CT.gov ↗
What to watch
Phase 1/2MelanomaActive not recruiting
Est. primary completion 2026-12 · NCT04283890 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2026-12 · NCT03340129 · CT.gov ↗
What to watch
Phase 2Pleural Biphasic Mesothelioma, Pleural Sarcomatoid MesotheliomaRecruiting
Est. primary completion 2026-12-15 · NCT05647265 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2026-12-20 · NCT04413123 · CT.gov ↗
What to watch
Phase 1Glioblastoma, GBM, Glioblastoma Multiforme, Grade IV AstrocytomaActive not recruiting
Est. primary completion 2026-12-30 · NCT04606316 · CT.gov ↗
What to watch
Phase 2Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder, Non-urothelial Upper Tract, Penile Cancer …Active not recruiting
Est. primary completion 2026-12-30 · NCT03333616 · CT.gov ↗
What to watch
Phase 2Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8 …Active not recruiting
Est. primary completion 2026-12-30 · NCT03776487 · CT.gov ↗
What to watch
Phase 1Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 …Recruiting
Est. primary completion 2026-12-31 · NCT06324240 · CT.gov ↗
What to watch
Phase 1Renal Cell CarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT02210117 · CT.gov ↗
What to watch
Phase 1Urothelial CarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT04388852 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT05597800 · CT.gov ↗
What to watch
Phase 2Uterine Cervical NeoplasmsRecruiting
Est. primary completion 2026-12-31 · NCT05492123 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2026-12-31 · NCT07155317 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT03297606 · CT.gov ↗
What to watch
2027 (75)
January 2027 (10)
Phase 2Bladder CancerActive not recruiting
Est. primary completion 2027-01 · NCT03520491 · CT.gov ↗
What to watch
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2027-01 · NCT03104439 · CT.gov ↗
What to watch
Phase 1Glioblastoma, Gliosarcoma, Adult, Glioblastoma - CategoryRecruiting
Est. primary completion 2027-01-01 · NCT07134842 · CT.gov ↗
What to watch
Phase 1/2Solid TumorRecruiting
Est. primary completion 2027-01-19 · NCT05584670 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-01-23 · NCT06250335 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-31 · NCT05176483 · CT.gov ↗
What to watch
Phase 1Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8Active not recruiting
Est. primary completion 2027-01-31 · NCT03816358 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-01-31 · NCT04079166 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-01-31 · NCT04462406 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-01-31 · NCT04472767 · CT.gov ↗
What to watch
February 2027 (5)
Phase 1/2Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors, SMARCA4-deficient Primary CNS Malignant Tumors …Active not recruiting
Est. primary completion 2027-02-01 · NCT05407441 · CT.gov ↗
What to watch
Phase 2Metastatic Soft-tissue SarcomaActive not recruiting
Est. primary completion 2027-02-01 · NCT04551430 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-02-05 · NCT06946797 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02-28 · NCT06047379 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2027-02-28 · NCT03866382 · CT.gov ↗
What to watch
March 2027 (8)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-03 · NCT07422753 · CT.gov ↗
What to watch
Phase 2/3Colorectal CancerActive not recruiting
Est. primary completion 2027-03 · NCT05141721 · CT.gov ↗
What to watch
Phase 1MelanomaRecruiting
Est. primary completion 2027-03-04 · NCT05498792 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-03-11 · NCT05289193 · CT.gov ↗
What to watch
Phase 3Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-03-11 · NCT03873402 · CT.gov ↗
What to watch
Phase 1/2Grade 2 Meningioma, Grade 3 Meningioma, Recurrent MeningiomaActive not recruiting
Est. primary completion 2027-03-19 · NCT03604978 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-03-31 · NCT03391869 · CT.gov ↗
What to watch
Early phase / not applicableMelanomaRecruiting
Est. primary completion 2027-03-31 · NCT07422779 · CT.gov ↗
What to watch
April 2027 (10)
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2027-04 · NCT04730544 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-04 · NCT07560488 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-04 · NCT03122522 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04-01 · NCT05254184 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-04-01 · NCT07751055 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal CarcinomaActive not recruiting
Est. primary completion 2027-04-05 · NCT03097939 · CT.gov ↗
What to watch
Phase 1Squamous Cell Carcinoma of the Head and NeckActive not recruiting
Est. primary completion 2027-04-09 · NCT03690986 · CT.gov ↗
What to watch
Phase 1/2Solid Tumor, Metastases to Soft TissueActive not recruiting
Est. primary completion 2027-04-23 · NCT03707808 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04-27 · NCT06364917 · CT.gov ↗
What to watch
Phase 2Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone, Malignant Solid Neoplasm …Active not recruiting
Est. primary completion 2027-04-30 · NCT03449108 · CT.gov ↗
What to watch
May 2027 (3)
Phase 2MelanomaRecruiting
Est. primary completion 2027-05 · NCT05384496 · CT.gov ↗
What to watch
Phase 1Colorectal CancerNot yet recruiting
Est. primary completion 2027-05-01 · NCT07587827 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-05-12 · NCT07919717 · CT.gov ↗
What to watch
June 2027 (7)
Phase 2MesotheliomaActive not recruiting
Est. primary completion 2027-06 · NCT03918252 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-06 · NCT03546686 · CT.gov ↗
What to watch
Phase 1Colorectal CancerActive not recruiting
Est. primary completion 2027-06-01 · NCT04117087 · CT.gov ↗
What to watch
Phase 1/2Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-06-30 · NCT01896999 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2027-06-30 · NCT04511013 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8Active not recruiting
Est. primary completion 2027-06-30 · NCT04751370 · CT.gov ↗
What to watch
Phase 2Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype, Secondary GlioblastomaActive not recruiting
Est. primary completion 2027-06-30 · NCT04145115 · CT.gov ↗
What to watch
July 2027 (3)
Phase 2Cancer of RectumRecruiting
Est. primary completion 2027-07 · NCT05732389 · CT.gov ↗
What to watch
Phase 2Basal Cell CarcinomaRecruiting
Est. primary completion 2027-07 · NCT03521830 · CT.gov ↗
What to watch
Phase 1Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-07-30 · NCT02496208 · CT.gov ↗
What to watch
August 2027 (5)
Phase 1MelanomaActive not recruiting
Est. primary completion 2027-08 · NCT06377111 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2027-08 · NCT05663775 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT07075120 · CT.gov ↗
What to watch
Phase 1Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Unresectable Malignant Solid NeoplasmActive not recruiting
Est. primary completion 2027-08-01 · NCT03502733 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2027-08-02 · NCT05896839 · CT.gov ↗
What to watch
September 2027 (6)
Phase 1/2Prostate CancerActive not recruiting
Est. primary completion 2027-09 · NCT01688492 · CT.gov ↗
What to watch
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2027-09 · NCT06594991 · CT.gov ↗
What to watch
Phase 1Advanced MalignanciesActive not recruiting
Est. primary completion 2027-09-30 · NCT03233139 · CT.gov ↗
What to watch
Phase 1MelanomaRecruiting
Est. primary completion 2027-09-30 · NCT04697576 · CT.gov ↗
What to watch
Phase 2Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic SyndromeActive not recruiting
Est. primary completion 2027-09-30 · NCT02530463 · CT.gov ↗
What to watch
October 2027 (4)
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-10-01 · NCT05361720 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-10-15 · NCT05012254 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-10-18 · NCT07227012 · CT.gov ↗
What to watch
Phase 2Dedifferentiated Liposarcoma, Recurrent Dedifferentiated Liposarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma …Active not recruiting
Est. primary completion 2027-10-31 · NCT03307616 · CT.gov ↗
What to watch
November 2027 (3)
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-11 · NCT03406247 · CT.gov ↗
What to watch
Phase 1/2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-11-02 · NCT07227415 · CT.gov ↗
What to watch
Phase 1Phase 1b, HC-7366, SHARK, Kidney CancerRecruiting
Est. primary completion 2027-11-30 · NCT07401875 · CT.gov ↗
What to watch
December 2027 (11)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-12 · NCT07506109 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2027-12 · NCT07230613 · CT.gov ↗
What to watch
Early phase / not applicableMelanomaRecruiting
Est. primary completion 2027-12 · NCT07364474 · CT.gov ↗
What to watch
Phase 1Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT02950766 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT04013542 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-31 · NCT06362369 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT02696993 · CT.gov ↗
What to watch
Phase 2Pan-tumorRecruiting
Est. primary completion 2027-12-31 · NCT04566380 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT05048212 · CT.gov ↗
What to watch
Early phase / not applicableMelanomaRecruiting
Est. primary completion 2027-12-31 · NCT07564570 · CT.gov ↗
What to watch
2028 (28)
January 2028 (2)
Phase 2MelanomaRecruiting
Est. primary completion 2028-01-01 · NCT05779423 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2028-01-30 · NCT06163820 · CT.gov ↗
What to watch
March 2028 (6)
Phase 2MelanomaRecruiting
Est. primary completion 2028-03 · NCT06999980 · CT.gov ↗
What to watch
Phase 3Renal Cell CarcinomaActive not recruiting
Est. primary completion 2028-03-01 · NCT03793166 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2028-03-17 · NCT05428007 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-03-19 · NCT07487662 · CT.gov ↗
What to watch
Phase 1Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease …Recruiting
Est. primary completion 2028-03-30 · NCT03816345 · CT.gov ↗
What to watch
Phase 2Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression …Active not recruiting
Est. primary completion 2028-03-31 · NCT02703623 · CT.gov ↗
What to watch
May 2028 (2)
Phase 2Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma …Active not recruiting
Est. primary completion 2028-05-15 · NCT05836571 · CT.gov ↗
What to watch
Phase 2MelanomaNot yet recruiting
Est. primary completion 2028-05-24 · NCT07511036 · CT.gov ↗
What to watch
June 2028 (3)
Phase 2Pancreatic Adenocarcinoma MetastaticRecruiting
Est. primary completion 2028-06 · NCT06747845 · CT.gov ↗
What to watch
Phase 2Biliary Tract Cancers (BTC)Active not recruiting
Est. primary completion 2028-06-30 · NCT07654530 · CT.gov ↗
What to watch
Phase 2Peritoneal Mesothelioma, First-line TherapyNot yet recruiting
Est. primary completion 2028-06-30 · NCT07893340 · CT.gov ↗
What to watch
July 2028 (2)
Phase 1/2MelanomaNot yet recruiting
Est. primary completion 2028-07 · NCT07615881 · CT.gov ↗
What to watch
Phase 4Oncology, Infusion ReactionRecruiting
Est. primary completion 2028-07 · NCT06031233 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1Renal Cell CarcinomaRecruiting
Est. primary completion 2028-08-25 · NCT07128680 · CT.gov ↗
What to watch
October 2028 (2)
Early phase / not applicableRenal Cell CarcinomaNot yet recruiting
Est. primary completion 2028-10-01 · NCT07233668 · CT.gov ↗
What to watch
Phase 2Gastric / Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-10-20 · NCT07878221 · CT.gov ↗
What to watch
November 2028 (3)
Phase 2MelanomaRecruiting
Est. primary completion 2028-11 · NCT06295159 · CT.gov ↗
What to watch
Phase 1/2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2028-11-01 · NCT05501054 · CT.gov ↗
What to watch
Early phase / not applicableMelanomaRecruiting
Est. primary completion 2028-11-05 · NCT04605146 · CT.gov ↗
What to watch
December 2028 (7)
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2028-12 · NCT06941857 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2028-12-15 · NCT06708949 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-12-30 · NCT06492408 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-30 · NCT06492421 · CT.gov ↗
What to watch
Phase 2Locally Advanced Gastric CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07638631 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2028-12-31 · NCT07611825 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07917767 · CT.gov ↗
What to watch
2029 (21)
March 2029 (3)
Phase 1Renal Cell CarcinomaRecruiting
Est. primary completion 2029-03 · NCT05536141 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2029-03 · NCT07740941 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-03-01 · NCT04248569 · CT.gov ↗
What to watch
April 2029 (2)
Phase 1Urothelial CarcinomaRecruiting
Est. primary completion 2029-04 · NCT07532902 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2029-04-12 · NCT07877194 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2029-05 · NCT07504796 · CT.gov ↗
What to watch
June 2029 (1)
Phase 1MelanomaRecruiting
Est. primary completion 2029-06-01 · NCT07501117 · CT.gov ↗
What to watch
July 2029 (2)
Phase 1/2MelanomaRecruiting
Est. primary completion 2029-07 · NCT06240143 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2029-07-15 · NCT07683221 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2CancerRecruiting
Est. primary completion 2029-08-25 · NCT03899155 · CT.gov ↗
What to watch
September 2029 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-09 · NCT07563738 · CT.gov ↗
What to watch
October 2029 (4)
Phase 2/3Locally Advanced Rectal Cancer (LARC)Not yet recruiting
Est. primary completion 2029-10-01 · NCT07879586 · CT.gov ↗
What to watch
Phase 2/3Locally Advanced Rectal Cancer (LARC)Not yet recruiting
Est. primary completion 2029-10-01 · NCT07879599 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-10-15 · NCT07291076 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2029-10-30 · NCT05187338 · CT.gov ↗
What to watch
November 2029 (4)
Phase 1MelanomaNot yet recruiting
Est. primary completion 2029-11-01 · NCT07838974 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-11-02 · NCT04665206 · CT.gov ↗
What to watch
Phase 1/2Renal Cell CarcinomaRecruiting
Est. primary completion 2029-11-28 · NCT07293351 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2029-11-30 · NCT07188896 · CT.gov ↗
What to watch
December 2029 (2)
Phase 2Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2029-12 · NCT07715565 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2029-12-30 · NCT07756190 · CT.gov ↗
What to watch
2030 (11)
January 2030 (1)
Phase 2/3MelanomaRecruiting
Est. primary completion 2030-01 · NCT06581406 · CT.gov ↗
What to watch
March 2030 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-03-31 · NCT06926790 · CT.gov ↗
What to watch
May 2030 (1)
Phase 1Renal Cell CarcinomaRecruiting
Est. primary completion 2030-05-03 · NCT07195682 · CT.gov ↗
What to watch
June 2030 (1)
Phase 1Neuroendocrine Carcinoma, Neuroendocrine TumorsRecruiting
Est. primary completion 2030-06-01 · NCT06889493 · CT.gov ↗
What to watch
August 2030 (1)
Phase 1/2MelanomaRecruiting
Est. primary completion 2030-08-16 · NCT06683755 · CT.gov ↗
What to watch
September 2030 (2)
Phase 1/2Triple-Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2030-09 · NCT07762703 · CT.gov ↗
What to watch
Phase 1/2Glioblastoma (GBM)Not yet recruiting
Est. primary completion 2030-09 · NCT07762716 · CT.gov ↗
What to watch
October 2030 (2)
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-10 · NCT07430202 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2030-10-21 · NCT07930182 · CT.gov ↗
What to watch
December 2030 (2)
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-12-12 · NCT04929041 · CT.gov ↗
What to watch
Phase 1/2Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue SarcomaRecruiting
Est. primary completion 2030-12-31 · NCT03138161 · CT.gov ↗
What to watch
2031 (7)
January 2031 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2031-01-01 · NCT03815890 · CT.gov ↗
What to watch
August 2031 (1)
Phase 1/2Renal Cell CarcinomaRecruiting
Est. primary completion 2031-08-01 · NCT06866262 · CT.gov ↗
What to watch
October 2031 (1)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2031-10-31 · NCT07689175 · CT.gov ↗
What to watch
December 2031 (4)
Phase 3Advanced Kidney CancerNot yet recruiting
Est. primary completion 2031-12 · NCT07338981 · CT.gov ↗
What to watch
Phase 1Soft Tissue SarcomasRecruiting
Est. primary completion 2031-12-31 · NCT07444619 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2031-12-31 · NCT07403877 · CT.gov ↗
What to watch
Phase 2/3Resectable Gastric/Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2031-12-31 · NCT07643623 · CT.gov ↗
What to watch
2032 (6)
February 2032 (1)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2032-02-18 · NCT05533697 · CT.gov ↗
What to watch
March 2032 (1)
Phase 2Colon CarcinomaRecruiting
Est. primary completion 2032-03-01 · NCT03026140 · CT.gov ↗
What to watch
April 2032 (1)
Phase 3MelanomaRecruiting
Est. primary completion 2032-04-15 · NCT06794775 · CT.gov ↗
What to watch
May 2032 (1)
Phase 3Metastatic Kidney Cancer, Metastatic Kidney CarcinomaRecruiting
Est. primary completion 2032-05-05 · NCT06364631 · CT.gov ↗
What to watch
July 2032 (2)
Phase 2Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma …Recruiting
Est. primary completion 2032-07-30 · NCT05112601 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-07-31 · NCT07355205 · CT.gov ↗
What to watch
2033 (2)
June 2033 (1)
Phase 2/3MelanomaActive not recruiting
Est. primary completion 2033-06-30 · NCT02339571 · CT.gov ↗
What to watch
August 2033 (1)
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2033-08-01 · NCT07510334 · CT.gov ↗
What to watch
2040 (1)
February 2040 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2040-02-28 · NCT07770100 · CT.gov ↗
What to watch

See the full readout calendar ↗